Traders and investors can benefit from pre-market movers since they give an early indication of future market movements. Alternative trading systems (ATSs) and electronic communication networks (ECNs) are two ways to trade pre-market movers. Since Pre-Market Movers have limited liquidity and volume, their bid-ask spreads are wide. The types of orders retail brokers can accept are usually limited when it comes to pre-market movers.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
It is worth paying attention to these five pre-market movers.
Quotient Limited
Quotient Limited (QTNT) shares were rising 58.31% to trade at $0.1276 in pre-market at the last check. QTNT’s stock lost -37.37% to close Monday’s session at $0.08. The stock volume remained at 18.68 million shares, which was higher than the average daily volume of 3.21 million shares within the past 50 days. QTNT shares have fallen by -96.81% over the last 12 months, and they have moved down by -39.53% in the past week. Over the past three months, the stock has lost -68.65%, while over the past six months, it has shed -86.67%. Further, the company has a current market of $10.93 million and its outstanding shares stood at 135.80 million.
Goldman rated the Quotient Limited (NASDAQ: QTNT) stock “Neutral”. Goldman’s estimates were contained in a research note released on Thursday, June 03, 2021. Several other experts on Wall Street have posted such reports regarding QTNT shares. According to BTIG Research, the stock is “a Buy,”$12. BTIG Research published its figures in a research note released to investors on Thursday, August 31, 2017. Other experts at UBS have the stock’s price target at $26 price; with their rating of the stock as “a Buy.”. These scores were published in a research note the firm released on Wednesday, November 04, 2015.
XPeng Inc.
XPeng Inc. (XPEV) has advanced 5.44% at $6.98 in pre-market trading hours on the last check Tuesday. The stock of XPEV lost -3.92% to complete the last trading session at $6.62. The price range of the company’s shares was between $6.47 and $6.85. It traded 27.74 million shares, which was above its daily average of 17.11 million shares over 100 days. XPEV’s shares have dropped by -7.54% in the last five days, while they have subtracted -44.60% in the last month. Further, it is currently trading at a price-to-book ratio of 1.02.
CTC LLC bought a fresh place in XPeng Inc. (NYSE: XPEV). The institutional investor bought 313.5 thousand shares of the stock in a transaction that took place on 9/30/2022. In another most recent transaction, which was held on 10/06/2022, IRISH LIFE INVESTMENT MANAGERS L bought approximately 28.0 thousand shares of XPeng Inc. In a separate transaction that took place on 9/30/2022, the institutional investor, STATE STREET GLOBAL ADVISORS FRA bought 21.2 thousand shares of the company’s stock. The total Institutional investors and hedge funds own 34.70% of the company’s stock.
RLX Technology Inc.
At last check in pre-market trading, shares of RLX Technology Inc. (RLX) were up 12.00% at $1.40. RLX’s stock closed the last session at $1.25, decreasing -7.41% or -$0.1. Shares of the company fluctuated between $1.25 and $1.41 throughout the day. The number of shares exchanged was 5.81 million, less than the company’s 50-day daily volume of 7.44 million and lower than its Year-to-date volume of 9.94 million. In the past 12 months, the company’s stock has advanced -74.28%, and in the last week, the stock has moved up 25.00%. For the last six months, the stock has lost a total of -39.02%, and over the last three months, the stock has decreased by -14.97%. The stock has returned -67.95% so far this year. Additionally, the stock is trading at a price-to-earnings ratio of 4.63.
Volatility is just a proportion of the anticipated day-by-day value extension—the range where an informal investor works. Greater instability implies more noteworthy benefit or misfortune. After an ongoing check, RLX Technology Inc. (NYSE: RLX) stock is found to be 23.06% volatile for the week, while 12.21% volatility is recorded for the month. The outstanding shares have been calculated at 1.32B. Based on a recent bid, its distance from 20 days simple moving average is 12.72%, and its distance from 50 days simple moving average is 3.10% while it has a distance of -37.43% from the 200-day simple moving average.
NIO Inc.
NIO Inc. (NIO) shares have gained 6.93% at $10.34 in Tuesday’s premarket session. NIO Inc.’s stock subtracted -0.21% to finish the last trading session at $9.67. The stock recorded a trading volume of 46.88 million shares, which is below the average daily trading volume published for the last 50 days of 52.81 million shares. The shares of NIO Inc. have retreated 2.33% in the last five days; however, they have lost -38.68% over the last month. The stock price has shed -52.08% over the last three months and has lost -75.46 percent so far this year. Additionally, it has a price-to-sales ratio that stands at 3.01.
Multiple groups of Wall Street analysts have recently been drawn to the NIO stock, with those at BofA Securities upgrading the stock to a “Buy”. The analysts released their assessment via a research note they published on May 16, 2022. Analysts at UBS maintained their earlier rating, although they did drop the stock’s price target to $32 from $42. Over at China Renaissance, the analysts restated the earlier stance about NIO Inc. shares, rating the shares “a Buy.” in a note released on March 24, 2022.
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals Inc. (PHAS) is rising on the charts today, up 41.49% to trade at $0.1463 at the last check in premarket trading. On Monday, shares in PhaseBio Pharmaceuticals Inc. fell -3.36% to close the day at $0.10. The volume of shares traded was 4.9 million, which is higher than the average volume over the last three months of 1.00 million. During the trading session, the stock oscillated between $0.099 and $0.126. The company had an earnings-per-share ratio of -2.13. PHAS’s stock has lost -26.61% of its value in the previous five sessions and -41.25% over the past month but has lost -96.04% on a year-to-date basis. The stock’s 50-day moving average of $0.6229 is above the 200-day moving average of $1.0346. Moreover, the stock is currently trading at an RSI of 17.58.
NEW ENTERPRISE ASSOCIATES 13 L, 10% Owner, of PhaseBio Pharmaceuticals Inc. (PHAS), sold 1,784,109 shares of PhaseBio Pharmaceuticals Inc. stock in an exchange that took place on Oct 25. The shares were sold at an average price of 0.15 each, amounting to a total Sale worth $262,264. As of the close of the Sale, 10% Owner now directly holds 4,857,525 shares of the organization’s stock, which is now worth about $485752.5. The deal was disclosed in a Securities & Exchange Commission legal filing, which can be publicly viewed on the SEC website.
